中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

44 records (took 0.024 seconds)

    RECEIVED MESSAGE VERIFICATION
    21.
    发明申请
    RECEIVED MESSAGE VERIFICATION 有权
    接收到的消息验证

    公开(公告)号：US20100275027A1

    公开(公告)日：2010-10-28

    申请号：US12667783

    申请日：2008-07-07

    Applicant: Caroline Belrose ,  Nicholas Bone ,  Timothy Wright

    Inventor： Caroline Belrose ,  Nicholas Bone ,  Timothy Wright

    IPC: H04L9/32 ,  H04M3/16

    CPC classification number: H04L63/104 ,  G06F21/305 ,  G06F21/575 ,  H04L63/12 ,  H04W12/10

    Abstract: A method of verifying the validity of a message received by a telecommunications terminal (8) having a processor (30) and which is operable in a boot mode and a runtime mode is disclosed. In the embodiments the message is a SIM unlock message, for removing or modifying a restriction of the types of subscriber identity module (SIM) with which the mobile terminal may be used. In response to reception of the SIM unlock message when the terminal (1) is in the runtime mode, the processor 30 of the terminal (1) causes the terminal to enter the boot mode and verify the validity of the message during the boot mode. Because the validity of the message is checked during the boot mode, the check can be performed with greater security.

    Abstract translation: 公开了一种验证由具有处理器（30）并且可以以引导模式和运行时模式操作的电信终端（8）接收的消息的有效性的方法。 在实施例中，消息是SIM解锁消息，用于去除或修改可以使用移动终端的订户身份模块（SIM）的类型的限制。 当终端（1）处于运行时模式时，响应于SIM卡解锁消息的接收，终端（1）的处理器30使终端进入引导模式，并在启动模式期间验证消息的有效性。 因为在启动模式期间检查消息的有效性，所以可以以更大的安全性执行检查。

    BANK ACCOUNT NUMBER VALIDATION
    24.
    发明申请
    BANK ACCOUNT NUMBER VALIDATION 审中-公开

    公开(公告)号：US20180068319A1

    公开(公告)日：2018-03-08

    申请号：US15811107

    申请日：2017-11-13

    Applicant: Bharathi Ramavarjula ,  Nimesh Parikh ,  Timothy Wright

    Inventor： Bharathi Ramavarjula ,  Nimesh Parikh ,  Timothy Wright

    IPC: G06Q20/42 ,  G06Q20/40 ,  G06Q20/32

    CPC classification number: G06Q20/425 ,  G06Q20/3255 ,  G06Q20/3274 ,  G06Q20/4016

    Abstract: A method for validating payment information for an online transaction is provided. A payment server can receive two representations of the same payment information. The payment information can be validated if it is determined that the two representations match. If there is no match, or the payment information is otherwise invalid, the payment information can be repaired based on a trusted representation of the payment information, such as stored payment information or an image of an associated value token. Payment information can be received via one or more communication channels, and can be provided by one or more consumer devices. A merchant service provider can validate payment information and handle transaction processing on behalf of a merchant.

    Use of IL-1beta compounds
    28.
    发明授权
    Use of IL-1beta compounds 有权
    使用IL-1β化合物

    公开(公告)号：US08409576B2

    公开(公告)日：2013-04-02

    申请号：US13283165

    申请日：2011-10-27

    Applicant: Phil Lowe ,  Hermann Gram ,  Thomas Jung ,  Timothy Wright ,  Trevor Mundel

    Inventor： Phil Lowe ,  Hermann Gram ,  Thomas Jung ,  Timothy Wright ,  Trevor Mundel

    IPC: A61K39/395 ,  C07K16/24 ,  C12P21/08

    CPC classification number: C07K16/245 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

    Abstract: This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

    Abstract translation: 本发明涉及使用IL-1和配体/ IL-1受体破坏化合物（本文中称为IL-1β化合物）的方法; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用，IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 如本文所述的结合分子。 本文公开的抗体，例如 IL-1和bgr 结合化合物或IL-1受体结合化合物，和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平，用于治疗和/或预防自身炎症综合征，例如， 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法，例如， 少年类风湿关节炎或成人类风湿关节炎综合征，在哺乳动物，特别是人类。

    Methods of treating arthritis using IL-1β binding molecules
    29.
    发明授权
    Methods of treating arthritis using IL-1β binding molecules 有权
    使用IL-1和bgr治疗关节炎的方法 结合分子

    公开(公告)号：US08105587B2

    公开(公告)日：2012-01-31

    申请号：US12090490

    申请日：2006-10-24

    Applicant: Phil Lowe ,  Hermann Gram ,  Thomas Jung ,  Timothy Wright ,  Trevor Mundel

    Inventor： Phil Lowe ,  Hermann Gram ,  Thomas Jung ,  Timothy Wright ,  Trevor Mundel

    IPC: A61K39/395 ,  A61K39/00 ,  C07K16/00 ,  C12P21/08

    CPC classification number: C07K16/245 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

    Abstract: This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

    Abstract translation: 本发明涉及使用IL-1和配体/ IL-1受体破坏性化合物（本文中称为“IL-1β化合物”）的方法; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用，IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 如本文所述的结合分子。 本文公开的抗体，例如 IL-1和bgr 结合化合物或IL-1受体结合化合物，和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平，用于治疗和/或预防自身炎症综合征，例如， 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法，例如， 少年类风湿关节炎或成人类风湿关节炎综合征，在哺乳动物，特别是人类。

Patent Agency Ranking